Publication Name	World Journal of Gastrointestinal Pharmacology and Therapeutics
Manuscript ID	110273
Country	United Kingdom

Category	Gastroenterology & Hepatology
Manuscript Type	Retrospective Study
Article Title	Risankizumab is effective following ustekinumab failure in Crohn’s disease: A real-world study from a tertiary center
Manuscript Source	Invited Manuscript
All Author List	Michael Colwill, Jessica Padley, Umang Qazi, Sonia Mehta, Fiona Donovan, Ana Margarida Alves, Richard Pollok, Kamal Patel, Patrick Dawson, Sailish Honap and Andrew Poullis
Funding Agency and Grant Number
Corresponding Author	Michael Colwill, MRCP, Department of Gastroenterology, St George's University Hospitals NHS Foundation Trust, Blackshaw Road, London SW17 0QT, London, United Kingdom. michael.colwill@stgeorges.nhs.uk
Key Words	Crohn's disease; Risankizumab; Ustekinumab; Advanced therapy
Core Tip	Despite evidence of superiority of risankizumab over ustekinumab when managing Crohn’s disease, it is unknown if switching from ustekinumab to risankizumab is effective. This retrospective study evaluated outcomes in 51 adults who switched from ustekinumab to risankizumab. Significant reductions in Harvey-Bradshaw Index scores were observed at all timepoints, with remission rates rising from 37.1% to 94.4% over 9 months. Albumin, C-reactive protein and calprotectin also improved. Patients with secondary loss of response to ustekinumab responded better than primary non-responders. No serious adverse events occurred. These findings support risankizumab as a safe, effective option after ustekinumab failure in refractory Crohn’s.
Citation	Colwill M, Padley J, Qazi U, Mehta S, Donovan F, Alves AM, Pollok R, Patel K, Dawson P, Honap S, Poullis A. Risankizumab is effective following ustekinumab failure in Crohn’s disease: A real-world study from a tertiary center. World J Gastrointest Pharmacol Ther 2025; In press

Received	2025-06-03 16:02
Peer-Review Started	2025-06-03 16:02
To Make the First Decision
Return for Revision	2025-06-19 09:12
Revised	2025-07-01 14:30
Second Decision	2025-09-05 02:40
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2025-09-05 08:25
Articles in Press	2025-09-05 08:25
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript

ISSN	2150-5349 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com